Nagi Bioscience

Nagi Bioscience is a Swiss startup operating in the biotechnology sector, specializing in laboratory technologies for next-generation alternative testing. The company's primary offering is the SydLab™ ONE, a technology that automates screenings on micro-organisms, allowing researchers to focus on their results rather than the testing process. This automation also provides unprecedented levels of standardization and reproducibility, which are crucial in scientific research.

Nagi Bioscience serves a diverse range of clients, including agrochemical companies and aging biotech companies. These clients utilize Nagi's technologies to identify adverse toxicology as early as possible in their R&D pipelines, reducing the cost of late-stage failures. The company's technologies also offer methodologies to assess lifespan and healthspan measures in a high-throughput manner, particularly in the C. elegans field, a model organism widely used in biological research.

The business model of Nagi Bioscience is centered around providing tailored services for exceptional research. By pioneering the Organism-on-Chip technologies, the company bridges the gap between cells and vertebrates seamlessly, making micro-organisms testing easy and efficient. The company generates revenue by selling their innovative technologies and providing services to their clients.

Keywords: Biotechnology, Laboratory Technologies, Micro-organisms Testing, Automation, Standardization, Reproducibility, Early Toxicology Identification, Lifespan and Healthspan Measures, Organism-on-Chip Technologies, Tailored Research Services.